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hypoxia; hypercapnia ORTHOSTATIC INTOLERANCE is defined by symptoms of lightheadedness, nausea, cognitive disability, diaphoresis, headache, fatigue, palpitations, and heat, which are present upright and resolve when recumbent. Postural tachycardia syndrome (POTS) is defined by orthostatic intolerance associated with excessive postural tachycardia, and in adults by an increase in sinus heart rate (HR) of Ͼ30 beats/min or to a HR Ͼ 120 beats/min during 10 min of orthostasis (16) .
Many POTS patients have dyspnea and hyperventilation when upright. Our group has reported the association of hyperpnea with thoracic hypovolemia and splanchnic hypervolemia in POTS (33) . Large decrements in end-tidal CO 2 (ETCO 2 ), often reaching 25 Torr or less, following change of position from supine to upright are driven by increased ventilation (18) . This results in cerebral vasoconstriction (25) , which may account, in part, for central symptoms of orthostatic intolerance. Evidence of hyperpnea in POTS patients occurs in the absence of any functional or structural cardiac or respiratory abnormalities. Candidate mechanisms for hyperpnea include a defect in chemoreflex response or in ventilatory control in these patients. There is no evidence supporting an intrinsic defect in chemoreception. Thus far baroreflex-chemoreflex interactions have not been studied in patients with POTS.
Respiratory chemoreceptors are of two types: peripheral and central. The peripheral receptors primarily respond to arterial hypoxia and to a lesser extent to hypercapnia (17) . The central receptors are far more sensitive to hypercapnia (increase in hydrogen ions) (4) . The peripheral chemoreceptors are contained within the carotid and aortic bodies, whereas the central chemoreceptors are currently believed to be distributed mainly in the medulla (5) .
Respiratory chemoreceptors can modulate the autonomic nervous system. The modulation can be indirect, via changes in blood O 2 and CO 2 concentration, or by inhibiting K ϩ channels, depolarizing chemosensitive neurons, and thereby increasing their firing rate (27, 31) . Modulation can also be direct via sympathetic facilitation (30) .
Baroreceptors can also modulate chemoreflex activity and ventilation. For example, ventilatory responses to chemoreceptor stimulation are augmented by arterial baroreceptor unloading and are depressed by baroreceptor loading (12) .
Based on these relationships, we tested the hypothesis that chemoreflex sensitivities are increased in POTS patients and are potentiated by orthostatic baroreflex unloading causing hyperventilation.
MATERIALS AND METHODS
The study was approved by the Institutional Review Board of New York Medical College, and informed consent was obtained from all subjects.
Subjects
We studied 20 POTS [16 women (W) and 4 men (M)] and 14 healthy subjects (10 W and 4 M) between the ages of 16 and 35 yr and with height of 169 Ϯ 9 cm, weight of 63.8 Ϯ 10.3 kg, and body mass index of 22.4 Ϯ 0.8 kg/m 2 (means Ϯ SE). All subjects were nonsmokers and normotensive. Subjects were not taking medications, and none of them had been at high altitude (Ͼ1,500 m) for at least 5 mo. Hemoglobin concentrations were normal and ranged from 10.2 to 17.4 mg/dl. Since hypovolemia and dehydration may increase ventilation, POTS patients were screened for evidence of hypovolemia and abnormal renin-angiotensin-aldosterone levels. None of the enrolled patients was hypovolemic or had any other hormonal or hematologic abnormalities. Because of the effects of the menstrual cycle on cardiovascular regulation (21) , all female subjects were studied during their early follicular phase (1-4 days after the onset of menstruation).
Experimental Setup
The ventilatory responses to eucapneic hypoxia and hyperoxic hypercapnia were obtained using the "dynamic end-tidal forcing" technique (34) . This technique allows for the manipulation of endtidal concentration of one gas while maintaining the end-tidal concentration for another gas constant. We used four gas conditions intended to separate the effects of hypoxia and hypercapnia on chemoreflex function: eucapneic normoxia (breathing room air), eucapneic hypoxia (10% O 2 balanced with N2 while maintaining ETCO2, unchanged from breathing room air), eucapneic hyperoxia (30% O2 while maintaining ETCO2 unchanged from breathing room air), and hypercapnic hyperoxia (30% O2 ϩ 5% CO2).
Eucapneic hypoxia was used to assess the hypoxic response attributed to peripheral chemoreflex sensitivity (PCS). Thirty percent O2 (hyperoxia) was used to minimize the PCS. Hyperoxic hypercapnia was used to measure the hypercapnic [central chemoreceptor sensitivity (CCS)] chemoreflex function by suppressing the effect of peripheral chemoreceptors (carotid body) with O 2 and stimulating central chemoreceptors with CO2 (23) . An open circuit was used to control inspired gases during each of these gas conditions. Open circuit breathing uses two-way valves to eliminate exhaled CO2 and uses premixed gases for inhalation.
Subjects breathed through a face mask connected to a pneumotachograph (Hans Rudolph, Shawnee, KS), from which we obtained inspired minute volumes. The other end of this pneumotachograph was connected through a low-resistance two-way nonrebreathing valve (Hans Rudolph), which had two outlets. One outlet of this nonrebreathing valve was used for expired gas and connected to a room air exhaust; the other end of the nonrebreathing valve was connected to a 30-liter breathing bag (Rusch, Teleflex Medical). The gas in the bag was constantly replenished with gases (O 2, CO2, and N2), mixed to the desired concentration using a rotameter (model FL-6GP, Omega Engineering, Stamford, CT). The inspired content of the bag was changed by varying the concentrations of O2, CO2, and N2. The breathing bag was always fully inflated at the start of inspiration, and excess gas was vented through an exhaust valve. The flow was modulated to ensure that a sufficient amount of gas was available during the increased ventilation induced by hypercapnia. Two stage gas flow regulators connected to each of the three air cylinders (O 2, N2, and CO2) were used to achieve constant flow at the desired concentration of the air mixture, balanced with N2 (5% CO2, 10% O2, 30% O2, balanced by N2). Inhaled O2 concentration was measured continuously and directly by an O2 sensor (S-3A/I Oxygen Analyzer with N-22M Sensor, AEI Technologies, Naperville, IL), attached near the face mask. ETCO2 was measured by nasal prongs connected to a side stream capnograph (Capnocheck sleep capnograph/oximeter, Smiths Medical, St. Paul, MN). The pneumotachograph was calibrated using a 3-liter syringe, and the O 2 sensor was calibrated using known concentrations of O2 before each testing session. A schematic diagram of the experimental setup is shown in Fig. 1 .
For eucapneic normoxia, the valves were adjusted so that subjects breathed room air. For eucapneic hypoxia, the level of O 2 was titrated so that subjects breathed 10% O2 (monitored by O2 sensor) for 8 min. During this time, subjects typically achieved an arterial O2 saturation (SaO 2 ) of ϳ80 -85% as assessed by pulse oximetry of the earlobe. For hyperoxia, the level of O2 was titrated so that subjects breathed 30% O2 (monitored by O2 sensor) for 8 min. For hypercapnic hyperoxia, the level of O2 and CO2 was titrated so that subjects breathed 30% O2 plus 5% CO2 to increase ETCO2 to 60 Torr or to 10 Torr more than baseline level (monitored by O2 sensor and by capnograph) for 8 min.
The ETCO2 levels were displayed in real time on the capnograph screen, ETCO2 giving an accurate noninvasive measurement of arterial PCO2 (28) . Subjects rested and breathed room air in between the hypoxic and hyperoxic conditions. Measurements of all respiratory and cardiovascular parameters were made once a steady state was achieved.
Protocol
Testing began at 10:00 AM after 4 h of fast. Subjects refrained from beverages containing xanthine and caffeine for at least 72 h before testing. Subjects were familiarized with the procedures used in the study. Subjects were instrumented for electrocardiography, respiratory plethysmography, Sa O 2 by pulse oxymetry, pneumotachography via a facemask, impedance plethysmography, continuous blood pressure recording, and capnography. After an initial 20 min of acclimatization, subjects were monitored during a 20-min rest period in which ETCO 2 was measured via a nasal cannula. Mean ETCO2 over the last 5 min of rest period was defined as isocapnia for the particular subject for the remainder of the protocol. Subjects then underwent four measurement periods separated by 30-min rest periods. Each measurement period corresponded to one of the following gas conditions presented in random order: eucapneic normoxia (room air), eucapneic hypoxia, eucapneic hyperoxia, and hypercapnic hyperoxia. We randomized the order of conditions between eucapneic normoxia, eucapneic hyperoxia, hyperoxic hypercapnia, and eucapneic hypoxia because the order of gas might effect the responses (13) . Subjects breathed gases for 8 min or until the subject requested to stop.
After all supine data collections were complete, the subjects were reintroduced to each gas condition for 1 min while supine and were tilted head-upright to 70°(HUT) for a maximum of 8 min in each gas condition. Continuous HR, mean arterial pressure (MAP), Sa O 2 , ETCO2, and minute ventilation (V E) were recorded. Subjects were tilted back to the supine position if fainting ensued or if the subject requested to stop. Cardiac output (CO) was estimated using the model flow method contained within the Finometer.
Data Analysis
Data were digitized at 200 Hz with signal processing software and analyzed off-line. Beat-to-beat data were collected during the last 3 min for HR, MAP (Finometer, TNO, Amsterdam, The Netherlands), Sa O 2 , ETCO2, and expiratory V E during supine and HUT in each of the gas conditions. Cardiovascular responses were further assessed by measuring MAP, systolic blood pressure (SBP), diastolic blood pressure (DBP), HR, CO, total peripheral resistance (TPR), and stroke volume (SV) during ventilatory changes.
MAP was calculated from SBP and DBP with the formula MAP ϭ (SBP ϩ 2·DBP)/3. TPR was calculated as MAP/CO. Ventilation versus gas content function curves were constructed with V E on the ordinate and the gas measure on the abscissa. The operating point was defined by room air (normoxia-eucapnia) for each subject.
Ventilatory PCS (response to hypoxia) was determined by calculating linear regression slopes between V E and SaO 2 (gas measure) during eucapneic hyperoxia to eucapneic hypoxia (the hypoxic ventilatory response).
Ventilatory central chemoreflex sensitivity (CCS) (response to hypercapnia) was determined by calculating linear regression slopes between V E and ETCO2 (gas measure) during eucapneic hyperoxia and hypercapnia.
Statistics
Measurements across the conditions were computed for PCS and CCS for each subject. Individual regression slopes between V E, hypoxia, and hypercapnia were averaged across each condition and compared for supine and HUT. Regressions for chemoreflex responses were compared across the two conditions during supine and HUT conditions using a two-way repeated-measures analysis of variance. Likewise, cardiovascular responses (HR, MAP, SBP, DBP, CO, TPR, and SV) were compared across supine and HUT conditions. When appropriate, post hoc comparisons were performed using Tukey's test. Primary outcome variables were correlated to find causal associations. Differences were considered significant when P Ͻ 0.05. All values are reported as means Ϯ SE unless otherwise indicated.
RESULTS
Out of 20 POTS (16 W and 4 M) and 14 control (10 W and 4 M) subjects, 19 POTS (15 W and 4 M) and 12 control (8 W and 4 M) subjects completed the eucapneic normoxia (room air HUT) protocol, 13 POTS (9 W and 4 M) and 6 control (5 W and 1 M) subjects completed the hyperoxic HUT protocol, 13 POTS (9 W and 4 M) and 6 control (5 W and 1 M) subjects completed the eucapneic hypoxia HUT protocol, and 9 POTS (5 W and 4 M) and 6 control (5 W and 1 M) subjects completed the hypercapnic hyperoxia HUT protocol. Data of patients completing each gas condition have been averaged and compared across groups. Group-averaged data for POTS and control subjects for every gas condition are shown for the supine position (Table 1 ) and upright position ( Table 2) .
Eucapneic Normoxia: Room Air
Supine: baseline conditions. POTS and control subjects had no significant differences in Sa O 2 , ETCO 2 , and respiratory rate while supine. However, POTS patients had a higher V E (P Ͻ 0.05), lower SBP (P Ͻ 0.05), and higher HR (P Ͻ 0.05) than control subjects. CO and TPR were not different, but SV was reduced in POTS compared with control subjects (P Ͻ 0.05) ( Table 1) .
HUT. Head-up tilt to 70°was used to unload the baroreflexes. Baroreflex unloading during HUT did not affect Sa O 2 and respiratory rate (Table 2) in either POTS or control subjects. When compared with controls, POTS patients had significantly higher V E (P Ͻ 0.05), lower ETCO 2 (P Ͻ 0.01), and higher HR (P Ͻ 0.01) than control subjects.
HUT decreased CO (P Ͻ 0.01) in controls. SV decreased (P Ͻ 0.001), HR increased (P Ͻ 0.001), and peripheral resistance increased (P Ͻ 0.05) in both POTS and control subjects (Table 2 ) compared with supine.
PCS: Eucapneic Hypoxia
Hypoxia supine. Hypoxia in the supine position decreased Sa O 2 in both POTS and control subjects (P Ͻ 0.001). However, controls trended toward larger decreases in Sa O 2 compared with POTS patients (Table 1) . A decrease in Sa O 2 initiates an increase in ventilation (29) in both POTS and control subjects (P Ͻ 0.05). Despite smaller decreases in Sa O 2 , POTS patients had a higher V E during hypoxia than control subjects (P Ͻ 0.05) (Fig. 2) . Thus, in the supine position, POTS patients had a trend toward higher hypoxic ventilatory response/PCS (in l·min Ϫ1 ·%oxygen Ϫ1 ) than controls (POTS vs. controls, 0.2 Ϯ 0.11 vs. 0.15 Ϯ 0.05, P ϭ 0.08). Both POTS and control subjects had an increase in their HR (P Ͻ 0.05) (POTS Ͼ controls, P Ͻ 0.01) and an increase in their COs (Table 1) .
Hypoxia HUT. When compared with room air HUT, hypoxia HUT decreased Sa O 2 (P Ͻ 0.001), increased V E, and increased HR in both POTS and control subjects (P Ͻ 0.001). However, POTS patients had higher V E (P Ͻ 0.05) and higher HR (P Ͻ 0.05) than controls (Fig. 2) . Hypoxia HUT did not change CO, TPR, MAP, CO, or SV (Table 2) .
Baroreflex unloading during hypoxia did not change the PCS in controls (supine vs. HUT, 0.15 Ϯ 0.05 vs. 0.19 Ϯ 0.017, P ϭ not significant) but increased PCS in POTS patients (0.2 Ϯ 0.11 to 0.42 Ϯ 0.38, P Ͻ 0.05). Thus PCS during HUT was higher in POTS than in control subjects (P Ͻ 0.05, Fig. 2 ).
In addition, the hypoxic response was reset, shifted upwards and to the right so that POTS patients had a higher V E and higher Sa O 2 than control subjects (Fig. 2) .
CCS: Hyperoxic Hypercapnia
Hyperoxic hypercapnia increased ventilation in both POTS and control subjects. During spontaneous breathing, hypercapnia is some 3-5 times stronger than hypoxia as a ventilatory stimulus under our experimental conditions (Table 1) .
Hypercapnia supine. When supine, POTS and control subjects had no significant differences in ETCO 2 . Hypercapnia increased ETCO 2 in both POTS and control subjects to similar levels with a trend toward higher V E in controls compared with POTS patients (P ϭ 0.08) (Fig. 3, and Table 1 ). The hypercapnic ventilatory response/CCS for POTS patients was lower than that for controls (0.68 Ϯ 0.34 vs. 1.0 Ϯ 0.18, P Ͻ 0.05).
At room air supine position, POTS patients had a trend toward higher ventilation than did controls (Table 1) . Room air hypercapnia caused a higher increase in ventilation in controls compared with POTS patients. Room air hypercapnia increased MAP and HR in both POTS and control subjects.
Hypercapnia HUT. Baroreflex unloading during hypercapnia HUT led to higher V E in controls compared with POTS patients (P Ͻ 0.05, Fig. 3 ). Sa O 2 was not different between POTS and control subjects (Table 2) .
When compared with room air HUT, hypercapnia HUT did not change CCS in controls (supine vs. HUT, 0.84 Ϯ 0.27 vs. 1.04 Ϯ 0.18, P ϭ not significant) but decreased CCS in POTS patients (0.68 Ϯ 0.34 vs. 0.49 Ϯ 0.38, P Ͻ 0.05). Upright CCS for POTS patients was markedly lower than for controls (HUT-CCS, POTS vs. controls, 0.49 Ϯ 0.38 vs. 1.04 Ϯ 0.18, P Ͻ 0.05).
DISCUSSION
The results of this study demonstrated an increased respiratory chemoreflex response to hypoxia and a decreased respiratory chemoreflex response to hypercapnia in POTS compared with control subjects, even while supine. These differences were enhanced by orthostasis. We therefore infer that PCS measured by the hypoxic ventilatory response was increased in POTS patients, whereas CCS measured by the hypercapnic ventilatory response was reduced in POTS patients. Baroreflex unloading during HUT potentiated the hypoxic response while further blunting the hypercapnic response. Therefore, in POTS patients, baroreflex unloading during HUT stimulates peripheral O 2 -dependent chemoreflexes causing hyperventilation that is unopposed by the restraining effects of hypocapnia. Thus it seems that respiratory chemoreflexes are impaired in POTS patients, and their function is further perturbed by baroreflex unloading resulting in hyperventilation.
Increased PCS and Set Point in POTS
Increased ventilation can be induced in healthy humans during severe orthostatic stress that produces extreme reductions in central blood volume and CO (14) . The hyperpneic response is therefore physiological in extremis.
In our earlier studies of POTS, we found that modest orthostatic stress initiates hyperpnea and hyperventilation, but not in control subjects. Hyperpnea in POTS patients was related to the enhanced thoracic hypovolemia and reduced CO in these patients (33, 35) . Enhanced thoracic hypovolemia results in excessive baroreflex unloading in POTS compared with control subjects, resulting in marked sympathoexcitation (3) . In addition to increased peripheral O 2 chemoreceptor sensitivity in POTS patients, we observed a resetting of the hypoxic ventilatory response toward higher Sa O 2 and V E. This is directionally similar to orthostatic resetting of the arterial baroreflex known to occur in all subjects but enhanced in POTS patients (10) . Thus a resetting of the peripheral chemoreceptor set point is expected when upright.
Baroreflex unloading could increase ventilation through direct sympathoexcitation of the respiratory center (33, 35) , through effects on the peripheral chemoreflex (6), or through interactions of baroreflex and chemoreflex afferents in the intermediate area of the nucleus tractus solitarius (22) . This could also be due to more localized effects of baroreflexmediated sympathetic vasoconstriction of arterioles supplying the carotid and aortic bodies. Reduced local blood flow might result in a neural discharge similar to that evoked by asphyxia, anoxemia (2), or nicotine and cyanide (1, 7, 19) . Indeed, McCloskey (20) showed that increased impulse traffic of the carotid sinus nerve is easily elicited by hypotension-induced reductions in carotid body blood flow.
Although overt hypotension is uncommon in POTS, intermittently reduced blood flow occurs whenever upright and might engender chemoreflex potentiation similar to potentiation caused by chronic intermittent hypoxia. Indeed, POTS patients have increased V E supine, similar to long-lasting increases in baseline respiratory activity and long-term facilitation of respiratory motor output in humans with intermittent hypoxia (26). 
Reduced Central Chemoreceptor Sensitivity in POTS
In contrast to the increased response to hypoxia, POTS patients demonstrated depressed V E responses to hypercapnia compared with control subjects. Hypercapnia is usually a strong ventilatory stimulus and excites the medullary respiratory center via changes in blood pH (9) . Hypercapnia may also influence sympathoexcitation at the rostral ventrolateral medulla (9) . We used hyperoxic hypercapnia to examine the ventilatory effects of central chemoreceptor stimulation while minimizing the effects of peripheral chemoreceptors that are primarily O 2 sensitive (15, 23) . The stimulation of carotid chemoreceptors facilitates central chemoreceptors; conversely, the inhibition of carotid chemoreceptors can blunt central chemoreceptors (24) . However, physiological blunting of the central chemoreceptors must have been small because no such effects were observed in control subjects. Thus the peripheral effects on central chemoreceptors cannot account for the reduced central chemoreceptor sensitivity in POTS compared with control subjects. One potential explanation for this reduced chemoreceptor sensitivity may relate to the profound reduction of the cardiovagal baroreflex in POTS patients despite enhanced sympathoexcitation (32) . The application of cholinergic agents on the ventrolateral surface of the medulla in areas where the central chemoreceptors may be located stimulates breathing, whereas the application of atropine inhibits ventilation (11) . Thus vagal withdrawal could account for central chemoreflex suppression; however, these experiments have only been performed in nonhuman mammals.
Clinical Implications for POTS
POTS patients have increased ventilation, especially when upright, related to sympathetic baroreflex stimulation and almost complete cardiovagal baroreflex withdrawal. Hypocapnia results because POTS patients have decreased sensitivity to CO 2 , whereas the response of the peripheral chemoreceptors to hypoxia is enhanced. Enhanced hypoxic sensitivity may contribute to the long-term facilitation of sympathoexcitation in these patients. Upright hyperventilation and hypocapnia reduces cerebral blood flow (8) and contributes to light-headedness and to cognitive impairment during daily life.
Limitations
Our study has several limitations. First, the cardiorespiratory effects observed in our study were induced by acute chemoreflex activation but suggest a chronic change in chemoreflex sensitivity whose origins remain unclear. Second, we did not test the effects of hypoxic hypercapnia. However, we were primarily interested in separating the ventilatory effects of O 2 and CO 2 . In retrospect, this could have further delineated the role and contribution of carotid bodies in peripheral and central chemoreceptor interactions. 
